Rheumatology

September 16, 2021

Hyperuricemia is associated with vascular, cardiac, and renal disease, as well as gout. However, the reliability of a single measurement in defining hyperuricemia is unclear.

September 15, 2021

The efficacy evaluation of golimumab is crucial for patients with psoriatic arthritis, particularly for treating skin manifestations and psoriasis symptoms.

September 15, 2021

While lifestyle habits are modifiable risk factors, changing them can be especially challenging for patients with rheumatoid arthritis, who must also deal with chronic inflammatory disease.

September 14, 2021

Early diagnosis and treatment of psoriatic arthritis leads to better long-term outcomes. Despite this, most patients have significant diagnostic delays.

September 14, 2021

Effective treatment for patients with moderate-to-severe rheumatoid arthritis can control symptoms quickly and slow disease progression. How should such patients be managed? Test your knowledge with this quiz.

September 13, 2021

“The COVID-19 pandemic has strongly impacted the lives of patients living with rheumatoid arthritis which has contributed to anxiety, depression, and reduced well-being.”

September 10, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 10, 2021.

September 10, 2021

“There is likely to be a bidirectional relationship between sleep and gout, as gout flares may be influenced by circadian rhythms, and sleep quality is likely to be influenced by gout flares,” investigators explained. “Given the morbidity associated with sleep problems, we should be vigilant regarding sleep health in our patients with gout.”

September 09, 2021

Disease activity, safety, and the occurrence of adverse events were similar in patients with juvenile idiopathic arthritis receiving either etanercept or the biosimilars Benepali and Erelzi.

September 08, 2021

Philip Conaghan, MBBS, PhD, discusses his presentation entitled, “Meaningful Improvements in WOMAC Pain and Physical Function in 3 Phase 3 Trials of Tanezumab in Patients With Moderate-to-Severe Osteoarthritis: A Responder Analysis.”